Korean leprosy bulletin (대한나학회지)

Society of Korean Leprologists (대한나학회)
권호 표지

The summary of recent relapse leprosy cases in Korea(2003-2007)

최근 5년간의 재발 한센병 환자에 대한 조사

Kim, Jong-Pill
김종필

  • Published : 20080600
⟨ Previous Next ⟩

Abstract

Relapse may occur the poor killing of M.leprae due to inadequate treatment in early onset relapse, and persisting M.leprae and drug resistance mutants in late onset relapse. The relapse of leprosy after the release from treatment(RFT) has profound implications for the public Hansen program including case management, compliance, disease transmission and control. For the understanding of recent characteristics of the leprosy relapse in Korea, we are summarized and reported the epidemiological factors. 23 relapse cases were reported in Korea from 2003 to 2007. Among 23 cases, 18 cases were the lepromatous type, and 3 cases were the tuberculoid type. The mean duration of past treatment was 16.4 years, and the mean interval to relapse was 28.5 years.

Keywords

References

  1. WHO : Risk of relapse in leprosy. WHO/CTD/LEP/94.1 WHO Geneva 1994
  2. Pattyn SR, Groenen G, Bourland J, at al: The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. Eur J Epidemiol. 1988 4:231-4 https://doi.org/10.1007/BF00144758
  3. 한국한센복지협회: 한센병 관리사업 현황 및 주요 지표. 한국한센복지협회 2008
  4. THELEP: Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Lepr Rev. 1987 58(4):325-37
  5. Waters MF: Relapse following various types of multidrug therapy in multibacillary leprosy. Lepr Rev. 1995 66(1):1-9
  6. Waters MF, Rees RJ, McDougall AC, at al: Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli. Lepr Rev. 1974 45(4):288-98
  7. Noordeen SK.: Elimination of leprosy as a public health problem: progress and prospects.Bull World Health Organ. 1995 73(1):1-6
  8. de la Cruz EC, Cellona RV, Balagon MV, et al: Primary dapsoneresistant leprosy in Cebu, Philippines; cause for concern.Int J Lepr Other Mycobact Dis. 1996 64(3):253-6
  9. Chen JK, Wang SY, Hou YH, at al: Primary dapsone resistance in China. Lepr Rev 1989 60:263-6
  10. Davey TF: "Release from control" in leprosy. Lepr Rev 1978 49: 195-202
  11. Touw-Langendijk EM, Naafs B: Relapses in leprosy after release from control. Lepr Rev. 1979 50: 123-7
  12. Waters MF, Rees RJ, Laing AB, at al: The rate of relapse in lepromatous leprosy following completion of twenty years of supervised sulphone therapy. Lepr Rev. 1986 57:101-9
  13. Ho CK, Lo KK.: Epidemiology of leprosy and response to treatment in Hong Kong. Hong Kong Med J. 2006 12(3):174-9
  14. Waters MF: Relapse following various types of multidrug therapy in multibacillary leprosy. Lepr Rev. 1995 66:1-9
  15. Jamet P, Ji B: Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis. 1992 60:525-35
  16. Chopra NK, Agarwal JS, Pandya PG: Impact of multidrug therapy on leprosy in Baroda district (Gujarat). Indian J Lepr. 1989 61:179-89
  17. Cellona RV, Balagon MF, dela Cruz EC, at al: Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis. 2003 71:308-19 https://doi.org/10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2
  18. Becx-Bleumink M: Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992 60:161-72
  19. Girdhar BK, Girdhar A, Kumar A.: Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev. 2000 Jun; 71(2):144-53
  20. Jamet P, Ji B.: Relapse after longterm follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group.Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):195-201
  21. Shetty VP, Wakade AV, Ghate SD at al: Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev. 2005 Sep;76(3): 241-52